5 260

Cited 31 times in

Long-term efficacy and tolerability of topiramate as add-on therapy in refractory partial epilepsy: an observational study.

 Yang-Je Cho  ;  Kyoung Heo  ;  Won-Joo Kim  ;  Sang Hyun Jang  ;  Yo Han Jung  ;  Byoung Seok Ye  ;  Dong Beom Song  ;  Byung In Lee 
 EPILEPSIA, Vol.50(8) : 1910-1919, 2009 
Journal Title
Issue Date
Adolescent ; Adult ; Aged ; Anticonvulsants/therapeutic use* ; Child ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Electroencephalography ; Epilepsies, Partial/drug therapy* ; Female ; Fructose/analogs & derivatives* ; Fructose/therapeutic use ; Humans ; Longitudinal Studies ; Magnetic Resonance Imaging ; Male ; Maximum Tolerated Dose ; Middle Aged ; Observation/methods ; Outcome Assessment (Health Care) ; Retrospective Studies ; Secondary Prevention ; Young Adult
Epilepsy ; Refractory ; Topiramate ; Efficacy ; Tolerability
PURPOSE: To evaluate the long-term efficacy and tolerability of topiramate (TPM) as add-on therapy in patients with refractory partial epilepsy. METHODS: This is a retrospective, single-center, long-term observational study. Patients fulfilling the criteria of medical intractability proposed by Berg et al. were entered into the study if they were newly prescribed TPM as add-on therapy between January 2000 and June 2002. The usual starting dosage of TPM was 50 mg/day and optimal-dose adjustments were made according to individual clinical responses. Efficacy and tolerability were analyzed every year during 5-year follow-up in the "intention-to-treat (ITT) population." Retention rate was estimated by Kaplan-Meyer analysis. RESULTS: A total of 125 patients were included in the study and 107 patients (85.6%) were followed for 5 years. Retention rate was 87.2% at 1 year and 64% at 5 years. At the end of 5 years, the median seizure frequency reduction rate was 69.0% and responder rate was 43.2% in the ITT population. Cumulative seizure-free rate (SFR) was 30.4% and the terminal 1-year SFR was 12.8% in the ITT population (20.0% in completers) at 5-year follow-up. Adverse events (AEs) occurred in 39.2% of patients, including significant AEs leading to antiepileptic drug (AED) withdrawal in 14.4%. The most common AEs were anorexia (16.0%), weight loss (10.4%), and gastrointestinal symptoms (8.8%). Concomitant AEDs were reduced in 25.0% of the completers. DISCUSSION: Low-dose and slow-dose escalation of TPM in add-on therapy for patients with refractory partial epilepsy is effective and well tolerated in long-term, individualized clinical practice
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Neurology (신경과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Won Joo(김원주) ORCID logo https://orcid.org/0000-0002-5850-010X
Ye, Byoung Seok(예병석) ORCID logo https://orcid.org/0000-0003-0187-8440
Lee, Byung In(이병인)
Jang, Sang Hyun(장상현)
Jung, Yo Han(정요한)
Cho, Yang Je(조양제)
Heo, Kyoung(허경)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.